Despite being the most common breast cancer subtype, hormone receptor-positive, HER2-negative breast cancer has shown minimal benefit from IO, likely due its immunologically “cold” phenotype, as evidenced by low levels of TILs and PD-L1 expression (<10%) [72]. This evidence concerns the gene ERBB2 and breast carcinoma.